Logo

Innovent's Mazdutide (IBI362) Meet its Primary Endpoint in P-II Study for the Treatment of Type 2 Diabetes

Share this
Innovent's Mazdutide (IBI362) Meet its Primary Endpoint in P-II Study for the Treatment of Type 2 Diabetes

Innovent's Mazdutide (IBI362) Meet its Primary Endpoint in P-II Study for the Treatment of Type 2 Diabetes

Shots:

  • The P-II study evaluate mazdutide (3.0/4.5/6.0mg) vs dulaglutide (1.5mg, SC, qw for 20wks.) or PBO in 252 patients with T2D
  • The trial met its 1EPs i.e., reduction in HbA1c levels & body weight, mean change from baseline to 20wk. in HbA1c levels in mazdutide (3.0/4.5/6.0mg) were −1.41%/−1.67%/−1.54% vs −1.35% & 0.03%; HbA1c ≤7.0% @20wk. (62.8%/74.4%/78.3%) vs 69.8% & 20.0%
  • Mean change from baseline to 20wk. in body weight were −7.14% for mazdutide (6.0mg) vs −2.69% & −1.38%, patients achieved HbA1c ≤7.0% & body weight reduction of ≥5% from baseline to 20wk. was 52.2% vs 14.0% & 0%, was safe & well-tolerated, and no patient withdrew due to AEs with no sev. hypoglycemia events. The safety profile was similar to prior results of mazdutide

Ref: Innovent | Image: Innovent

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions